Eesti - eesti - Ravimiamet

pfizer limited - polümüksiin b+neomütsiin+gramitsidiin - silmatilgad - 10ml 1tk

Euroopa Liit - eesti - EMA (European Medicines Agency)

pfizer europe ma eeig - vorikonasool - candidiasis; mycoses; aspergillosis - antimükoosid süsteemseks kasutamiseks - voriconazole, on laia toimespektriga, triasooli seenevastaste agent ja on näidustatud täiskasvanutel ja lastel vanuses 2 aastat ja üle järgmiselt:ravi invasiivse aspergillosis;ravi kohta candidaemianon-neutropenic;patsientide ravi fluconazole-resistentsete raskete invasiivsete candida infektsioonid (sealhulgas c. krusei);ravi raskete seente poolt põhjustatud infektsioonide scedosporium spp.. ja fusarium spp. vfend tuleb manustada peamiselt patsientidele, kellel on progresseeruv, võib-olla eluohtlikud infektsioonid. profülaktika invasiivsete seeninfektsioonide kõrge riskiga allogeense vereloome tüvirakkude siirdamise (hsct) saajad.

Euroopa Liit - eesti - EMA (European Medicines Agency)

pfizer europe ma eeig - tofacitinib - artriit, reumatoidartriit - immunosupressandid - rheumatoid arthritistofacitinib in combination with methotrexate (mtx) is indicated for the treatment of moderate to severe active rheumatoid arthritis (ra) in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying antirheumatic drugs (dmards) (see section 5. tofacitinib can be given as monotherapy in case of intolerance to mtx or when treatment with mtx is inappropriate (see sections 4. 4 ja 4. psoriatic arthritistofacitinib in combination with mtx is indicated for the treatment of active psoriatic arthritis (psa) in adult patients who have had an inadequate response or who have been intolerant to a prior disease modifying antirheumatic drug (dmard) therapy (see section 5. ulcerative colitistofacitinib is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (uc) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent (see section 5. tofacitinib is indicated for the treatment of active polyarticular juvenile idiopathic arthritis (rheumatoid factor positive [rf+] or negative [rf-] polyarthritis and extended oligoarthritis), and juvenile psoriatic arthritis (psa) in patients 2 years of age and older, who have responded inadequately to previous therapy with disease modifying antirheumatic drugs (dmards). tofacitinib can be given in combination with methotrexate (mtx) or as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. ankylosing spondylitistofacitinib is indicated for the treatment of adult patients with active ankylosing spondylitis (as) who have responded inadequately to conventional therapy.

Eesti - eesti - Ravimiamet

pfizer europe ma eeig - medroksüprogesteroon - tablett - 500mg 30tk

Eesti - eesti - Ravimiamet

pfizer europe ma eeig - flukonasool - kõvakapsel - 150mg 6tk; 150mg 500tk; 150mg 60tk; 150mg 4tk; 150mg 20tk; 150mg 10tk; 150mg 3tk; 150mg 30tk; 150mg 28tk

Eesti - eesti - Ravimiamet

pfizer europe ma eeig - eplerenoon - õhukese polümeerikattega tablett - 25mg 20tk; 25mg 50tk; 25mg 10tk; 25mg 100tk; 25mg 200tk; 25mg 28tk; 25mg 30tk

Eesti - eesti - Ravimiamet

pfizer europe ma eeig - amlodipiin - suus dispergeeruv tablett - 10mg 30tk; 10mg 10tk; 10mg 60tk; 10mg 90tk; 10mg 20tk; 10mg 100tk

Eesti - eesti - Ravimiamet

pfizer europe ma eeig - klindamütsiin - vaginaalsuposiit - 100mg 3tk

Eesti - eesti - Ravimiamet

pfizer europe ma eeig - amlodipiin - suus dispergeeruv tablett - 5mg 30tk; 5mg 60tk; 5mg 90tk; 5mg 100tk; 5mg 20tk; 5mg 500tk

Eesti - eesti - Ravimiamet

pfizer europe ma eeig - sultamitsilliin - suukaudse suspensiooni pulber - 50mg 1ml 30ml 1tk